

How caffeine affects alpha-amylase : an *in vivo* study

Farnaz Banakar¹, Raheleh Kheirbakhsh², Elnaz Mahrampour³, Azadeh Ebrahim-Habibi^{4*}

1. *Metabolic Disorders Research Centre, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Iran.*
2. *Cancer models research center, Cancer institute of Iran, Tehran University of Medical Sciences, Tehran, Iran.*
3. *Endocrinology and Metabolism Research Center, Endocrinology and Metabolism - Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.*
4. *Biosensor Research Center, Endocrinology and Metabolism Molecular-Cellular Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran.*

***Corresponding Author**

Azadeh Ebrahim-Habibi: Biosensor Research Center, Endocrinology and Metabolism Molecular- Cellular Sciences Institute, Tehran University of Medical Sciences, Shariati Hospital, North Kargar Avenue, 1411413137 Tehran, Iran.
Tel: +98 21 84902787; Fax: +9821 88220052
Email address: aeHabibi@sina.tums.ac.ir, azadehabibi@yahoo.fr

Running Title: caffeine on the liver and alpha-amylase gene expression.

Abstract

Background: Caffeine is a widely consumed psychostimulant with various effects, including on weight metabolic parameters. Blood glucose levels increase and reduced insulin sensitivity have been reported over caffeine consumption. Since xanthine derivatives like caffeine can activate alpha-amylase, an enzyme essential for carbohydrate-to-glucose conversion, this study investigates whether this translates to increased amylase activity in living organisms and explores potential gene expression changes.

Methods: Male NMRI mice were divided to 5 groups with 6 mice per group (total of 30 mice): Control (C), sham (sh) and three treated groups T30, T50 and T60 (receiving 30, 50, or 60 mg caffeine, respectively, by gavage, once a day for two weeks. Body weight was measured at the end of the experiment, after what blood sugar, alpha-amylase levels and gene expression as well as cholesterol levels were measured.

Results: Body weight of mice which had received the highest dose of caffeine (60mg/ml) for three weeks had significantly decreased compared with the other groups. However, blood sugar, serum alpha-amylase and cholesterol levels showed no significant differences between various groups. Levels of hepatic alpha amylase gene expression were significantly higher in the T30 group.

Conclusion: In conclusion, our findings suggest that caffeine's effect on hepatic alpha-amylase, an enzyme potentially important in metabolism, could hold significance for understanding and treating metabolic diseases.

Key words: Caffeine; Purine; Alpha-amylase; Amy Expression; NMRI mice; Blood sugar

Introduction

Caffeine is a purine compound that is widely consumed worldwide as part of various beverages; it could be considered as the most available and used edible “drug”, with various effects ranging from the well-known “alertness” and performance at work (1) to ergogenic effect in athletes (2), and potential neuroprotective ones in neurodegenerative diseases which may be related to its interaction with adenosine receptors (3-5).

Other reported helpful effects of caffeine include reduced risk of cardiovascular diseases leading to “improved survival” (6), reduced risk of liver cancer (7), possible improvement of alopecia when used in its topical form (8) and more recently, potentially reducing viral reproduction in SARS-CoV-2 (9). As with any other substance, there are known adverse effects associated with caffeine, such as possibility of hypertension (10) or anxiety (11), and even withdrawal syndrome (12).

Numerous studies concern caffeine’s effect on metabolic disorders, such as obesity and diabetes. Caffeine is reported to increase blood glucose levels and reduce insulin sensitivity in diabetic patients (13) and impair glucose tolerance in lean, obese and diabetic persons (14). Actually, increase of blood glucose, when measured shortly after a single dose of caffeine consumption had been already observed since the late 60s (15). Overall, glucose homeostasis is widely reported to be negatively affected by caffeine (16), and related to a decrease of glucose uptake by skeletal muscles (17).

In a previous (*in vitro*) study (18), we had found that alpha-amylase could be activated by xanthine derivatives, including caffeine. Alpha-amylase is an enzyme that is involved in the production of glucose from carbohydrate; more specifically, it acts on substrates like starch which contain alpha-1,4-glycosidic bonds. It catalyzes the hydrolysis of those bonds, which results into the production of smaller sugar molecules such as maltose and maltotriose. We had hypothesized that the observed increase of amylase activity could be related to the reported effect of caffeine on blood glucose-as one possible mechanism (18). As a continuation of that study, we have tested here the effect of caffeine ingestion in NMRI mice on biochemical parameters (e.g. blood glucose levels and alpha-amylase) as well as liver alpha- amylase expression, since liver alpha-amylase was observed to increase in obese mice (19).

Material and Methods

Animals and treatment

Mice (NMRI, male, a total of 30) were acquired from Pasteur institute (Karaj-Iran). One week was allowed for acclimatization of the mice to laboratory conditions. Throughout the three-week study period, the mice received a standard laboratory chow and had unrestricted access to water. Following a seven-day adjustment phase, their average weight was recorded at 25±2 grams. After their acclimatization period, the mice were allocated at random into five distinct groups, each consisting of six mice per group: the Control group (C), the Sham group (sh), and three experimental groups labeled T30, T50, and T60. These experimental groups were administered doses of 30, 50, and 60 milligrams of caffeine, respectively, via oral gavage on a daily basis over the course of two weeks.

The sham group received water instead, by gavage (as caffeine solvent), while the Control group was not exposed to any gavage. The experimental protocol was approved by the ethics committee of Endocrinology and Metabolism Research Institute (EMRI) (code: EC00311).

Measured factors

Body weight was measured weekly. Following the experimental period, the mice were humanely euthanized with an intraperitoneal injection of ketamine/xylazine at a dosage of 100/7.5 mg/kg (20). The collected blood samples were then spun at 3000 rpm for a duration of 5 minutes. The concentrations of Blood Sugar (BS), Alpha-Amylase (Amy), and Cholesterol (Chol) in these samples were determined using Pars Azmoon Co., Iran commercial kits through a photometric analysis technique."

mRNA extraction and cDNA synthesis

1 ml TRizol reagent was added to micro tubes containing 1 mg homogenized mouse liver tissue. RNA extraction was then carried out by Trizol reagents (Invitrogen) according to manufacturer's instructions. RNA precipitates were reconstituted in 100 µl of DEPC-treated water and subsequently preserved at -80°C. The assessment of RNA integrity and quantity was conducted by evaluating the OD260/280 ratios and OD260 values, utilizing a NanoDrop spectrophotometer (Thermo Scientific NanoDrop 2000). Samples exhibiting an OD260/280 ratio below 1.6 were excluded from the study. For cDNA synthesis, First Strand cDNA Synthesis Kit (Thermo Science) was used as the manufacturer recommends.

Quantitative real-time PCR

To assess the expression level of Amy 1 mRNA, we performed quantitative real-time PCR using the SYBR Premix Ex Taq II kit (Takara, Japan) and an ABI StepOne™ Sequence Detection System (Applied Biosystems, CA, USA). The reactions were set up in 98-well plates with a final volume of 20 µl, comprising 10 µl of 2× SYBR Premix Ex Taq, DNase, 1 µl of forward and reverse primers (1 µM each), 7.2 µl of deionized water, 0.2 µl of ROX dye, and 1.5 µl of 10-fold diluted cDNA. The housekeeping gene hypoxanthine-guanine phosphoribosyltransferase (HPRT) was used for normalization. The procedure was based on kit manufacturer (ThermoFisher Scientific) guidelines. Each PCR reaction was performed in duplicate using specific oligonucleotide primers for amplification. Real-time PCR was performed with an initial denaturation step of 10s at 95°C, 40 cycles at 95 °C for 5 s and 61°C for 30s.

Statistical Analysis

The data was analyzed by SPSS software. T-test followed by sample independent t-test were used to compare difference between experimental groups. The criterion for statistical significance was $p \leq 0.05$. Results were presented as mean $\pm$ SD.

Results

Body weight and Biochemical factors

As observed in Table 1, body weight of mice which had received the highest dose of caffeine (60mg/ml) for two weeks had decreased compared with the other groups, while other parameters including blood glucose levels, cholesterol and alpha-amylase levels had no significant differences between various groups.

Table 1: Measured weight and biochemical parameters. $p < 0.05$ was considered significant (*).

Groups	Body Weight (mean $\pm$ SD)	BS. (mean $\pm$ SD)	Chol. (mean $\pm$ SD)	α -amylase (mean $\pm$ SD)
Control	41 $\pm$ 2.7	202 $\pm$ 19.5	135 $\pm$ 28	2626 $\pm$ 354
Sham	40 $\pm$ 3	226 $\pm$ 23	139 $\pm$ 30	2596 $\pm$ 218
T30	40 $\pm$ 4	184 $\pm$ 61	151 $\pm$ 30	2513 $\pm$ 414
T50	38 $\pm$ 4	224 $\pm$ 18	180 $\pm$ 14	2455 $\pm$ 285
T60	37 $\pm$ 3*	194 $\pm$ 27	149 $\pm$ 27	2277 $\pm$ 403

Alpha amylase gene expression

As shown in Table 2, levels of hepatic alpha amylase gene expression are somewhat different (higher) in the treated groups compared with control group, although we found a significance only in the T30 group.

Table 2: Liver alpha-amylase gene expression in different groups. $p < 0.05$ was considered significant (*).

Groups	Control (mean $\pm$ SD)	Sham (mean $\pm$ SD)	T30 (mean $\pm$ SD)	T50 (mean $\pm$ SD)	T60 (mean $\pm$ SD)
Alpha-amylase gene expression	0.89 $\pm$ 0.40	1.29 $\pm$ 0.78	1.58 $\pm$ 0.79*	1.53 $\pm$ 0.74	1.37 $\pm$ 0.65

Discussion:

Although caffeine is generally reported to increase blood glucose levels via decreasing glucose uptake by skeletal muscles or affecting epinephrine, large scale studies seem to find a positive effect for caffeine in reducing the risk or delaying the appearance of diabetes; these findings could be related either to a difference between acute and chronic ingestion of caffeine, or the

fact that these studies are usually about “coffee” that contains other substances (17). A report on an animal model of diabetes suggests that chronic consumption of caffeine (60 days), can improve glucose tolerance and decrease blood glucose levels in diabetic animals (while no effect is seen in healthy ones). This effect could be related to either antioxidant, thermogenic, adenosine receptor antagonism or affecting glucose transport mechanism (21). An eight-week study on cases with hypercholesterolemia has also demonstrated that green/roasted coffee beans could ameliorate metabolic syndrome-related parameters (blood glucose and lipid levels) (22). As so, chronic vs acute use, as well as caffeine dose (23) may actually be of importance in amelioration or deterioration of the metabolic state. To name a recent study, acute consumption of coffee in humans was not affecting serum glucose levels; however, the study points to other carbohydrate-rich intake that existed throughout the study time (24). In our study too, blood glucose levels were not found to be increased in the caffeine treated group compared with control group. On the other hand, we found a significant decrease in weight in the treated group that was receiving the highest dose of caffeine. A previous study on rats has shown that caffeine intake can improve muscle thermogenesis (25), while fat oxidation and decreased leptin has also been observed in humans upon regular caffeine intake (26), resulting into weight loss. Additionally, appetite suppression, which a recent study has shown to correlate with the rate of coffee metabolism, may be another contributing factor (27). The effect of coffee on lipid profile is suggested to be dependent on the method of beverage preparation and the components that would be more present. Consequently, boiled coffee increases serum cholesterol, but due to the higher presence of diterpenes, while filtered coffee is devoid of this effect (28). It could be that the previous studies pointing to a rise of cholesterol linked with “caffeine” would have not differentiated those components effect (29). In our study too, no effect was observed on the cholesterol levels of the animals upon caffeine consumption. Finally, we have observed an effect of caffeine on alpha-amylase gene expression, but not on its serum levels. This is actually a potentially important effect, although only found in the T30 group, since we had previously suggested a relation between liver alpha-amylase increase (both on serum and gene expression levels) and early stages of obesity. Alpha-amylase inhibition is considered a potential aid in diabetes (30), while on the other hand, presence of low amylase levels in serum has been associated with insulin resistance (31), but this is an effect related to the disease itself, and has not been analyzed in details (especially with the definition of a threshold). What has been observed in the current study could be related to the duration of the treatment, dosage of the compound, and the fact that we had healthy mice. Based on these results, it could be interesting to find caffeine effect on obese mice alpha-amylase levels.

Conclusion

In summary, our study found no significant increase in blood glucose levels in caffeine-treated groups, but a notable decrease in body weight at the highest dose, aligning with previous findings on caffeine's role in weight loss. The impact on lipid profiles depends on coffee preparation methods, with no effect observed in the present study. Our key finding was an increase in hepatic alpha-amylase expression in the T30 group. Unlike its more well-known counterparts in the pancreas and saliva, hepatic alpha-amylase is a relatively understudied enzyme, and it is now suggested to be important in metabolic processes, especially with regard to weight control. This warrants further investigation, especially in obese models.

224

225 **Conflict of interests:**

226 The authors have no conflict of interests.

227

228 **Acknowledgments:**

229 This project has been supported by Endocrinology and Metabolism Research Institute (EMRI) affiliated to
230 Tehran University of Medical Sciences (project no:1392-01-106-1483). It has been performed mainly at
231 Biosensor Research Center, Endocrinology and Metabolism Molecular -Cellular Sciences Institute and in the
232 labs of Endocrinology and Metabolism Research Center, Endocrinology and Metabolism - Clinical Sciences
233 Institute, all affiliated with Tehran University of Medical Sciences, Tehran, Iran.

References:

- (1) Smith, A. P. Caffeine at work. *Human Psychopharmacology: Clinical and Experimental* **2005**, *20* (6), 441-445.
- (2) Paluska, S. A. Caffeine and exercise. *Current sports medicine reports* **2003**, *2* (4), 213-219.
- (3) Rivera-Oliver, M.; Díaz-Ríos, M. Using caffeine and other adenosine receptor antagonists and agonists as therapeutic tools against neurodegenerative diseases: a review. *Life sciences* **2014**, *101*, 1-9.
- (4) Schepici, G.; Silvestro, S.; Bramanti, P.; Mazzon, E. Caffeine: An Overview of Its Beneficial Effects in Experimental Models and Clinical Trials of Parkinson's Disease. *International Journal of Molecular Sciences* **2020**, *21* (13), 4766.
- (5) Pan, L.; Ma, Y.; Li, Y.; Wu, H.; Huang, R.; Cai, Z.; Wu, X. The Therapeutic Potential of Purinergic Receptors in Alzheimer's Disease and Promising Therapeutic Modulators. *Mini Reviews in Medicinal Chemistry* **2020**, *21*(11), 1288-1302.
- (6) Chieng, D.; Kistler, P. M. Coffee and Tea on Cardiovascular Disease (CVD) prevention. *Trends in Cardiovascular Medicine* **2021**, *32*(7):399-405.
- (7) Inoue, M.; Tsugane, S. Coffee drinking and reduced risk of liver cancer: Update on epidemiological findings and potential mechanisms. *Current nutrition reports* **2019**, *8* (3), 182-186.
- (8) Völker, J. M.; Koch, N.; Becker, M.; Klenk, A. Caffeine and Its Pharmacological Benefits in the Management of Androgenetic Alopecia: A Review. *Skin Pharmacology and Physiology* **2020**, *33* (3), 93-109.
- (9) Romero-Martínez, B. S.; Montaña, L. M.; Solís-Chagoyán, H.; Sommer, B.; Ramírez-Salinas, G. L.; Pérez-Figueroa, G. E.; Flores-Soto, E. Possible Beneficial Actions of Caffeine in SARS-CoV-2. *International Journal of Molecular Sciences* **2021**, *22* (11), 5460.
- (10) Adamczak, M.; Wiecek, A. Food Products That May Cause an Increase in Blood Pressure. *Current hypertension reports* **2020**, *22* (1), 1-8.
- (11) van Calker, D.; Biber, K.; Domschke, K.; Serchov, T. The role of adenosine receptors in mood and anxiety disorders. *Journal of neurochemistry* **2019**, *151* (1), 11-27.
- (12) Sajadi-Ernazarova, K. R.; Anderson, J.; Dhakal, A.; Hamilton, R. J. Caffeine withdrawal. In: *StatPearls [Internet]*. Treasure Island (FL): StatPearls Publishing; **2024** . Available from: <https://www.ncbi.nlm.nih.gov/books/NBK430790/>
- (13) Dewar, L.; Heuberger, R. The effect of acute caffeine intake on insulin sensitivity and glycemic control in people with diabetes. *Diabetes & Metabolic Syndrome: Clinical Research & Reviews* **2017**, *11*, S631-S635.
- (14) Robinson, L. E.; Savani, S.; Battram, D. S.; McLaren, D. H.; Sathasivam, P.; Graham, T. E. Caffeine ingestion before an oral glucose tolerance test impairs blood glucose management in men with type 2 diabetes. *The Journal of nutrition* **2004**, *134* (10), 2528-2533.
- (15) Cheraskin, E.; Ringsdorf Jr, W. M. Blood-glucose levels after caffeine. *Lancet* **1968**, *292* (7569), 689.
- (16) Petrie, H. J.; Chown, S. E.; Belfie, L. M.; Duncan, A. M.; McLaren, D. H.; Conquer, J. A.; Graham, T. E. Caffeine ingestion increases the insulin response to an oral-glucose-tolerance test in obese men before and after weight loss. *The American journal of clinical nutrition* **2004**, *80* (1), 22-28.
- (17) Zaharieva, D. P.; Riddell, M. C. Caffeine and glucose homeostasis during rest and exercise in diabetes mellitus. *Applied Physiology, Nutrition, and Metabolism* **2013**, *38* (8), 813-822.
- (18) Kashani-Amin, E.; Yaghmaei, P.; Larijani, B.; Ebrahim-Habibi, A. Xanthine derivatives as activators of alpha-amylase: Hypothesis on a link with the hyperglycemia induced by caffeine. *Obesity research & clinical practice* **2013**, *7* (6), e487-e493.
- (19) Mojbafan, M.; Afsartala, Z.; Amoli, M. M.; Mahmoudi, M.; Yaghmaei, P.; Larijani, B.; Ebrahim-Habibi, A. Liver alpha-amylase gene expression as an early obesity biomarker. *Pharmacological Reports* **2017**, *69* (2), 229-234.

- (20) Buitrago, S.; Martin, T. E.; Tetens-Woodring; J., Belicha-Villanueva, A.; Wilding, G. E.. Safety and efficacy of various combinations of injectable anesthetics in BALB/c mice. *Journal of the American Association for Laboratory Animal Science*, **2008**, 47(1), 11-17.
- (21) Urzúa, Z.; Trujillo, X.; Huerta, M.; Trujillo-Hernández, B.; Ríos-Silva, M.; Onetti, C.; Ortiz-Mesina, M.; Sánchez-Pastor, E. Effects of chronic caffeine administration on blood glucose levels and on glucose tolerance in healthy and diabetic rats. *Journal of International Medical Research* **2012**, 40 (6), 2220-2230.
- (22) Sarriá, B.; Martínez-López, S.; Sierra-Cinos, J. L.; García-Diz, L.; Mateos, R.; Bravo-Clemente, L. Regularly consuming a green/roasted coffee blend reduces the risk of metabolic syndrome. *European journal of nutrition* **2018**, 57 (1), 269-278.
- (23) Santos, R. M. M.; Lima, D. R. A. Coffee consumption, obesity and type 2 diabetes: A mini-review. *European journal of nutrition* **2016**, 55 (4), 1345-1358.
- (24) Marcus, G. M.; Rosenthal, D. G.; Nah, G.; Vittinghoff, E.; Fang, C.; Ogomori, K.; Joyce, S.; Yilmaz, D.; Yang, V.; Kessedjian, T. Acute effects of coffee consumption on health among ambulatory adults. *New England Journal of Medicine* **2023**, 388 (12), 1092-1100.
- (25) Clark, K. S.; Coleman, C.; Shelton, R.; Heemstra, L. A.; Novak, C. M. Caffeine enhances activity thermogenesis and energy expenditure in rats. *Clinical and Experimental Pharmacology and Physiology* **2019**, 46 (5), 475-482.
- (26) Westerterp-Plantenga, M. S.; Lejeune, M. P.; Kovacs, E. M. Body weight loss and weight maintenance in relation to habitual caffeine intake and green tea supplementation. *Obesity research* **2005**, 13 (7), 1195-1204.
- (27) Gkouskou, K. G.; Georgiopoulos, G.; Vlastos, I.; Lazou, E.; Chaniotis, D.; Papaioannou, T. G.; Mantzoros, C. S.; Sanoudou, D.; Eliopoulos, A. G. CYP1A2 polymorphisms modify the association of habitual coffee consumption with appetite, macronutrient intake, and body mass index: results from an observational cohort and a cross-over randomized study. *International Journal of Obesity* **2022**, 46 (1), 162-168.
- (28) Rebello, S. A.; van Dam, R. M. Coffee consumption and cardiovascular health: getting to the heart of the matter. *Current cardiology reports* **2013**, 15 (10), 403.
- (29) Shirlow, M. J.; Mathers, C. D. Caffeine consumption and serum cholesterol levels. *International journal of epidemiology* **1984**, 13 (4), 422-427.
- (30) Bosi, S.; Bregola, V.; Dinelli, G.; Trebbi, G.; Truzzi, F.; Marotti, I. The nutraceutical value of grain legumes: characterisation of bioactives and antinutritionals related to diabetes management. *International Journal of Food Science & Technology* **2019**, 54 (10), 2863-2871.
- (31) Nakajima, K. Low serum amylase and obesity, diabetes and metabolic syndrome: A novel interpretation. *World journal of diabetes* **2016**, 7 (6), 112.

List of Abbreviations

- C: Control group
- Sh: the Sham group
- T30: Experimental group receiving 30 mg caffeine/day
- T50: Experimental group receiving 50 mg caffeine/day
- T60: Experimental group receiving 60 mg caffeine/day
- BS: Blood Sugar
- Amy: Alpha-Amylase
- Chol: Cholesterol
- HPRT: Housekeeping gene hypoxanthine-guanine phosphoribosyltransferase